Alopecia areata
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Alopecia areata ka kitea i muri i te mahunga. I roto i ngā ahuatanga angamaheni, ka puta ohorere, te mata maeneene, me te rahi 2–3 cm.
relevance score : -100.0%
ReferencesKo te Alopecia areata he āhua e whakaekea ana e te pūnaha immune ki ngā makawe, ka ngaro ngā makawe mō te wā poto, ā, kāore e pakaru. Ka puta ake he pātanga o ngā makawe, ka pā ki te mahunga katoa, ki te tinana rānei, ā, ka pā ki te 2 % o ngā tangata i ētahi wā o tō rātou oranga. Ko te mea nui ko te pakaru i roto i te tiaki taiao huri noa i ngā makawe.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Ko te Alopecia areata he āhua ka whakaekehia e te punaha raupatu i ngā makawe, ka mate ngā makawe ki te mahunga me ētahi atu wāhanga o te tinana. Ka pā ana ki te 2 % o ngā tāngata o te ao. Ahakoa ka puta mai i ngā reanga katoa, he nui ake te pā o te hunga tamariki i te hunga pakeke (1.92 % vs. 1.47 %). Ko ngā wāhine, inā koa ko te hunga neke atu i te 50, ka nui ake te pā i ngā tāne. Ko te werohanga corticosteroids tika ki ngā wāhi kua pāngia, kua kitea he pai ake ngā hua atu i te whakapanga ki runga.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Ko te Alopecia areata e whakaponohia ana he mate autoimmune e pā ana ki te punaha raupatu o ngā makawe. Ko te tikanga, ko te korenga o te tinana ki te mōhio ki ōna ake pūtau, me te whakangaromanga o ngā makawe i muri mai.
○ Maimoatanga ― OTC Drugs
Ko ētahi tāngata whai alopecia areata ngawari ka ora i roto i te tau kāore he rongoā. Engari, ko te nuinga o ngā tāngata ka wheako i ngā hokinga mai i ngā wāhi ohorere i runga i te mahunga.
#Hydrocortisone cream
○ Maimoatanga
Ko ngā werohanga pūtaiaki intralesional te maimoatanga tino whai hua. Ka taea te whakamātautau i te whakamaoritanga o te mate mēnā ka pā ki ngā wāhi nui o te mahunga.
#Triamcinolone intralesional injection
#DPCP immunotherapy